OBI Pharma announces acquisition of cancer drug candidate from Threshold Pharmaceuticals

Taipei, Taiwan-headquartered OBI Pharma, Inc., (TPex: 4174), announced last week that an agreement with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) had been made to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3).

Read more

Taiwan eyes opportunities in precision medicine industry

Taiwan’s biotech and pharmaceutical industry was one of the first to be named in the original Tsai Administration’s 5+2 economic policy to transform the nation’s economic structure, and is viewed as the upcoming medical treatment trend that Taiwan cannot miss out on, said Johnsee Lee, the Honorary Chairman of Taiwan Bio Industry Organization (Taiwan BIO) during the Precision Medicine Industry Forum 2017 in Taipei, Wednesday.

Read more

GNTbm to begin Phase III clinical trial in Taiwan of Chidamide for breast cancer

GNT Biotech & Medicals Co., Ltd., (GNTbm) (TPEx: 7427) has announced that the anticancer drug Chidamide (HBI-8000), an epigenetic regulator developed by Chipscreen Biosciences Ltd., of Shenzhen, China, had received approval from the Taiwan Food and Drug Administration (TFDA) to begin a Phase III clinical trial in Taiwan for hormone receptor-positive, HER-2 negative late stage breast cancer.

Read more